StockData

BioCryst Pharmaceuticals vs Insmed

BCRX and INSM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BCRX and INSM compare

Insmed is the larger company, worth 14 times as much as BioCryst Pharmaceuticals ($26.7B against $1.9B).

Insmed grew revenue faster over the last twelve months (240% versus 68.7% for BioCryst Pharmaceuticals).

Insmed keeps more of each dollar of sales as profit, with a net margin of −39.9% compared with −40.9% at BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals scores higher on the StockData Score (9 against 8 for Insmed), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBCRXINSM
Size and price
Market cap$1.9B$26.7B
Share price$7.50$121.86
Change, 1 year5.9%−36.9%
Change, 5 years−39.9%321%
Beta (5Y)0.580.84
Employees4351,664
StockData Score
Total score9 (better)8
Valuation score1 (better)0
Growth score4 (better)3
Performance score22
Health score23 (better)
Dividend score00
Valuation
P/S2.0× (better)17.6×
P/B–36.8×
P/FCF5.1×–
FCF yield19.5% (better)−2.3%
Fair value–$61.10
Margin of safety–−99.5%
Growth
Revenue growth (TTM)68.7%240% (better)
Revenue growth, 5Y average118% (better)29.8%
Profitability
Gross margin97.8% (better)84.4%
Operating margin−33.3% (better)−37.1%
Net margin−40.9%−39.9% (better)
FCF margin39.7% (better)−41.3%
Return on equity–−72.5%
Financial health
Debt / equity–0.76
Interest coverage−4.2× (better)−6.9×
Current ratio2.322.86 (better)
Altman Z-score−3.837.42 (better)
Piotroski F-score7 (better)4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions103%102%
Held by insiders1.9%0.89%
Insider net buying, 12 months−$4.1M (better)−$133M
Superinvestors holding–1
Short interest, % of float11.0%6.5%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.